Skip to main content
SpringerLink
Log in

Ruxolitinib wirksam und gut verträglich

Behandlungsoption bei Polycythaemia vera

  • infopharm
  • Published:
Info Onkologie Aims and scope

Unter der Therapie mit Ruxolitinib besserte sich die Krankheitskontrolle bei Polycythaemia vera in einer Phase-III-Studie deutlich.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Media Roundtable & Webcast Event „Pivotal new research in rare blood disease polycythemia vera“ anlässlich der ASCO-Jahrestagung, Chicago, IL/USA, 2. Juni 2014; Veranstalter: Novartis Pharma

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Silke Wedekind

Authors
  1. Silke Wedekind
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wedekind, S. Ruxolitinib wirksam und gut verträglich. Info Onkol. 17, 56 (2014). https://doi.org/10.1007/s15004-014-0953-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0953-4

Search

Navigation